Clinical Report: Comparison of High-Dose and Standard-Dose Influenza Vaccines
Overview
This meta-analysis evaluates the effectiveness of high-dose inactivated influenza vaccine (HD-IIV) compared to standard-dose inactivated influenza vaccine (SD-IIV) in preventing severe clinical outcomes in older adults. Findings indicate that HD-IIV is associated with reduced hospitalizations for pneumonia or influenza and all causes.
Background
Influenza poses a significant health risk to older adults, who are more susceptible to severe complications and have a diminished immune response to standard vaccines. High-dose vaccines were developed to enhance immunogenicity and protection in this vulnerable population. Understanding the comparative effectiveness of HD-IIV versus SD-IIV is crucial for optimizing vaccination strategies in older adults.
Data Highlights
Outcome
Relative Vaccine Effectiveness (rVE)
95% Confidence Interval
Hospitalizations for pneumonia or influenza
38.5%
26.5%–48.5%
Laboratory-confirmed influenza
31.2%
19.3%–41.4%
Pneumonia or influenza
11.5%
5.9%–16.8%
Cardiorespiratory disease
7.5%
4.7%–10.3%
All causes
3.3%
1.8%–4.8%
Key Findings
HD-IIV contains four times the antigen of SD-IIV, enhancing immune response in older adults.
HD-IIV demonstrated a relative vaccine efficacy of 24.2% compared to SD-IIV in preventing laboratory-confirmed influenza.
The FLUNITY-HD study showed superior protection of HD-IIV against hospitalizations for pneumonia or influenza and cardiorespiratory disease.
A meta-analysis of 105,685 participants indicated that HD-IIV is associated with reduced hospitalizations for pneumonia or influenza compared to SD-IIV.
Recent trials have expanded the evidence base, including nearly 500,000 additional randomized participants.
Clinical Implications
The findings support the use of HD-IIV in older adults to reduce the risk of severe influenza-related outcomes. Healthcare providers should consider HD-IIV as a preferred option for vaccination in this population.
Conclusion
The meta-analysis provides robust evidence that HD-IIV is more effective than SD-IIV in preventing severe clinical outcomes in older adults. This supports the ongoing recommendation for HD-IIV in this high-risk group.
by Kristoffer Grundtvig Skaarup, Mats C. H. Lassen, Kaveh Hosseini, Niklas Dyrby Johansen, Matthew M. Loiacono, Rebecca C. Harris, Sandrine I. Samson, Arto A. Palmu, Kevin McConeghy, Stefan Gravenstein, Orly Vardeny, Brian Claggett, Scott D. Solomon, Federico Martinón-Torres, Tor Biering-Sørensen
